Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients

Korean Journal of Internal Medicine

Volumn 25, Issue 2, 2010, Pages 201-206

  Kim, Hyun Hee ^a   Kim, Jihun ^a   Park, Sung Hoon ^a   Kim, Seong Kyu ^a   Kim, Ok Dong ^a   Choe, Jung Yoon ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Arthritis; Cyclic citrullinated peptide; Joint disease; Rheumatoid; Rheumatoid factor

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT INJURY; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FEMALE; FINGER JOINT; HUMANS; MALE; METACARPOPHALANGEAL JOINT; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WRIST JOINT;

EID: 77954519318     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.2.201     Document Type: Article

References (30)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):1-12.
2. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
3. De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63: 1587-1593.
4. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63: 1090-1095.
5. Shmerling RH. Testing for anti-cyclic citrullinated peptide antibodies: is it time to set this genie free? Arch Intern Med 2009;169:9-14.
6. Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 2007;26:499-504.
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-851.
8. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402.
9. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
10. Meyer O, Nicaise-Roland P, Santos MD, et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006;8:R40.
11. Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 2004;37:495-501.
12. Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006;45:478-480.
13. Rau R, Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol 1995;22:1976-1982.
14. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004;50:3085-3092.
15. Emery P. The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 1994;33:765-768.
16. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996;124:699-707.
17. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-874.
18. Hoffman IE, Peene I, Pottel H, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 2005;51:261-263.
19. Nell VP, Machold KP, Eberl G, Stamm TA, Uffimann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-914.
20. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-2602.
21. van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:274-279.
22. Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-1736.
23. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964;23:302-305.
24. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hambin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979;2:97-99.
25. Vincent C, de Keyser F, Masson-Bessiere C, Sebbag M, Veys EM, Serre G. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 1999;58:42-48.
26. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-281.
27. Caspi D, Anouk M, Golan I, et al. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum 2006;55:53-56.
28. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008;67:1557-1561.
29. Syversen SW, Landewe R, van der Heijde D, et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009;36:1769-1784.
30. Zhao J, Liu X, Wang Z, Li Z. Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis. Clin Rheumatol 2010;29:33-38.